<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>World Business Briefing | Europe: Ireland: H.I.V. Test Approved</title>
    <meta content="MB000911" name="slug"/>
    <meta content="30" name="publication_day_of_month"/>
    <meta content="12" name="publication_month"/>
    <meta content="2003" name="publication_year"/>
    <meta content="Tuesday" name="publication_day_of_week"/>
    <meta content="Business/Financial Desk" name="dsk"/>
    <meta content="1" name="print_page_number"/>
    <meta content="W" name="print_section"/>
    <meta content="2" name="print_column"/>
    <meta content="Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="1547012"/>
      <doc.copyright holder="The New York Times" year="2003"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Acquired Immune Deficiency Syndrome</classifier>
        <classifier class="indexing_service" type="descriptor">Tests and Testing</classifier>
        <org class="indexing_service">Trinity Biotech</org>
        <org class="indexing_service">Food and Drug Administration</org>
        <person class="indexing_service">Lavery, Brian</person>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business/World Business</classifier>
        <classifier class="online_producer" type="general_descriptor">Acquired Immune Deficiency Syndrome</classifier>
        <classifier class="online_producer" type="general_descriptor">Acquired Immune Deficiency Syndrome</classifier>
        <classifier class="online_producer" type="general_descriptor">Tests and Testing</classifier>
        <classifier class="online_producer" type="general_descriptor">Viruses</classifier>
        <classifier class="online_producer" type="general_descriptor">Diseases and Conditions</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20031230T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9803E0DC103EF933A05751C1A9659C8B63" item-length="113" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>World Business Briefing | Europe: Ireland: H.I.V. Test Approved</hl1>
      </hedline>
      <byline class="print_byline">By Brian Lavery (NYT)</byline>
      <byline class="normalized_byline">Lavery, Brian</byline>
      <abstract>
        <p>World Busi</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>An Irish manufacturer of diagnostic medical devices, Trinity Biotech, received approval from the Food and Drug Administration for Uni-Gold Recombigen, an H.I.V. test that provides results in 10 minutes and is the only test that can screen serum, plasma and whole blood, the company said. The product is already used extensively in Africa, and Trinity has recently increased its sales force in the United States in anticipation of approval by the F.D.A.</p>
        <p>Brian Lavery (NYT)</p>
      </block>
      <block class="full_text">
        <p>An Irish manufacturer of diagnostic medical devices, Trinity Biotech, received approval from the Food and Drug Administration for Uni-Gold Recombigen, an H.I.V. test that provides results in 10 minutes and is the only test that can screen serum, plasma and whole blood, the company said. The product is already used extensively in Africa, and Trinity has recently increased its sales force in the United States in anticipation of approval by the F.D.A.</p>
        <p>Brian Lavery (NYT)</p>
      </block>
    </body.content>
  </body>
</nitf>
